Sort
48,018 grants matching “immunotherapy”
Targeting HIV-specific CAR T cells to the gut for the durable remission of HIV
$674,347Pamela J Skinner · University Of Minnesota · R01 · FY2024 · DK
A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX
$674,275Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2025 · CA
A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX
$674,275Juan Fernando Vera · Marker Therapeutics, Inc. · R44 · FY2024 · CA
Enhancing cell therapy for brain tumors
$674,256Catherine Mary Bollard · Children'S Research Institute · U01 · FY2018 · CA
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
$674,251Ellis L Reinherz · Dana-Farber Cancer Inst · R01 · FY2025 · CA
Functional Antibody Repertoire Against S. aureus Leukocidins after Invasive Human Infection
$674,014Isaac P Thomsen · Vanderbilt University Medical Center · R01 · FY2020 · AI
Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer
$673,898Kwok Kin Wong · New York University School Of Medicine · R01 · FY2025 · CA
Clinical Protocol and Data Management
$673,875Melissa Ann Geller · University Of Minnesota · P30 · FY2024 · CA
SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT
$673,851Mark Lewis · Bioqual, Inc. · N01 · FY2019 · AI
Neoadjuvant Immunotherapy Platform Study Reveals Mechanisms of Response in Hepatocellular Carcinoma (HCC)
$673,789Mark Yarchoan · Johns Hopkins University · R01 · FY2025 · CA
TRAINING GRANT IN MOLECUCLAR IMAGING RESEARCH AND CANCER SYSTEMS ANALYSIS
$673,738Ralph Weissleder · Massachusetts General Hospital · T32 · FY2025 · CA
N-glycosylation and Immunotherapy for cancer
$673,731Michael Demetriou · University Of California-Irvine · U01 · FY2021 · CA
N-glycosylation and Immunotherapy for cancer
$673,731Michael Demetriou · University Of California-Irvine · U01 · FY2022 · CA
PD-1 modulation of SIV specific CD4 and CD8 T cell responses
$673,668Francois J Villinger · Emory University · R01 · FY2010 · AI
TRAINING GRANT IN MOLECUCLAR IMAGING RESEARCH AND CANCER SYSTEMS ANALYSIS
$673,624Ralph Weissleder · Massachusetts General Hospital · T32 · FY2024 · CA
Adoptive MHC-E-Restricted T Cell Therapy for the Treatment of Chronic Hepatitis B Virus Infection
$673,614Benjamin J Burwitz · Oregon Health & Science University · R01 · FY2023 · AI
Development of Immunologic therapies against uveitis
$673,604Charles E Egwuagu · National Eye Institute · ZIA · FY2023 · EY
Neuro-immune modulation of pain in health and disease
$673,569Christopher Ryan Donnelly · Duke University · R01 · FY2023 · DE
CD200R blockade for cancer immunotherapy
$673,569Sujit Basu · Ohio State University · R01 · FY2025 · CA
Neuro-immune modulation of pain in health and disease
$673,569Christopher Ryan Donnelly · Duke University · R01 · FY2025 · DE
Home-based actigraphy to predict disability progression and enhance clinical trials in multiple sclerosis
$673,559Ellen M. Mowry · Johns Hopkins University · R01 · FY2023 · NR
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
$673,408Antonio M Omuro · Yale University · R01 · FY2023 · CA
Autoimmunity in Cardiopulmonary Toxicities from Radiotherapy and Immunotherapy
$673,394Bo Lu · Thomas Jefferson University · R01 · FY2022 · CA
A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis
$673,379Gary Fanger · Rise Therapeutics, Llc · SB1 · FY2024 · DK
Studying phenotypic states of antitumor human T cells
$673,212Sri Krishna · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA